Profile data is unavailable for this security.
About the company
Allakos Inc. is a clinical-stage biotechnology company, which is engaged in the development of therapeutics that target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases. The Company’s most advanced product candidate, AK006, is in a Phase I clinical trial. AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. It is developing AK006 for the treatment of CSU and potentially other indications. AK006 has completed preclinical testing, and in these studies, it has demonstrated that binding of AK006 to Siglec-6 inhibits multiple modes of mast cell activation, including IgE, IL-33, KIT, C5a and MRGPR-X2. In addition to mast cell inhibition, AK006 reduced human tissue mast cells via ADCP in the presence of activated macrophages. The Company is also developing lirentelimab (AK002) and, in conjunction with the Phase II, lirentelimab results in atopic dermatitis and chronic spontaneous urticaria.
- Revenue in USD (TTM)0.00
- Net income in USD-214.44m
- Incorporated2012
- Employees131.00
- LocationAllakos Inc825 INDUSTRIAL ROAD, SUITE 500SAN CARLOS 94070United StatesUSA
- Phone+1 (650) 597-5002
- Fax+1 (302) 655-5049
- Websitehttps://www.allakos.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eledon Pharmaceuticals Inc | 0.00 | -39.85m | 118.99m | 20.00 | -- | 1.02 | -- | -- | -1.41 | -1.41 | 0.00 | 3.02 | 0.00 | -- | -- | 0.00 | -48.86 | -38.44 | -51.95 | -39.80 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 54.16 | -- | -- | -- |
| Rezolute Inc | 0.00 | -58.21m | 120.38m | 51.00 | -- | 1.70 | -- | -- | -1.14 | -1.14 | 0.00 | 1.77 | 0.00 | -- | -- | 0.00 | -52.46 | -58.48 | -55.28 | -63.38 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -26.13 | -- | 92.29 | -- |
| Omega Therapeutics Inc | 4.94m | -92.28m | 120.79m | 93.00 | -- | 2.92 | -- | 24.46 | -1.67 | -1.67 | 0.0896 | 0.7498 | 0.029 | -- | 6.08 | 53,107.53 | -54.28 | -- | -62.10 | -- | -- | -- | -1,868.35 | -- | -- | -- | 0.302 | -- | 49.25 | -- | 5.13 | -- | -- | -- |
| Coya Therapeutics Inc | 6.13m | -10.30m | 121.33m | 8.00 | -- | 3.74 | -- | 19.80 | -0.8899 | -0.8899 | 0.5401 | 2.22 | 0.2236 | -- | -- | 766,131.30 | -37.59 | -- | -41.86 | -- | -- | -- | -168.11 | -- | -- | -- | 0.00 | -- | -- | -- | 34.77 | -- | -- | -- |
| Amylyx Pharmaceuticals Inc | 398.00m | -71.10m | 122.41m | 384.00 | -- | 0.3771 | -- | 0.3076 | -1.07 | -1.07 | 5.74 | 4.77 | 0.9644 | 6.74 | 21.00 | 1,036,461.00 | -17.23 | -- | -20.84 | -- | 88.93 | -- | -17.86 | -- | 4.48 | -- | 0.00 | -- | 1,612.94 | -- | 124.84 | -- | -- | -- |
| Regulus Therapeutics Inc | 0.00 | -31.37m | 123.73m | 28.00 | -- | 1.15 | -- | -- | -1.46 | -1.46 | 0.00 | 1.64 | 0.00 | -- | -- | 0.00 | -41.50 | -53.74 | -45.91 | -76.96 | -- | -- | -- | -715.58 | -- | -- | 0.005 | -- | -- | -- | -6.05 | -- | 94.54 | -- |
| Sangamo Therapeutics Inc | 18.76m | -328.05m | 123.97m | 405.00 | -- | 2.15 | -- | 6.61 | -1.86 | -1.86 | 0.1057 | 0.2784 | 0.0659 | -- | 4.86 | 46,311.11 | -115.20 | -26.09 | -139.17 | -31.04 | -- | -- | -1,749.06 | -136.53 | -- | -- | 0.00 | -- | 58.34 | 15.85 | -34.09 | -- | -13.25 | -- |
| Biostem Technologies Inc | 16.69m | -7.86m | 125.58m | 67.00 | -- | -- | -- | 7.53 | -0.5699 | -0.5699 | 1.21 | -0.0607 | -- | -- | -- | -- | -- | -- | -- | -- | 92.44 | -- | -47.12 | -- | 0.7825 | -10.22 | 1.26 | -- | -- | -- | -- | -- | -- | -- |
| China Health Industries Holdings, Inc. | 117.28k | -1.51m | 125.84m | 32.00 | -- | -- | -- | 1,072.96 | -0.023 | -0.023 | 0.0018 | -0.0349 | 0.0044 | 0.5692 | 25.25 | 3,665.00 | -5.72 | 3.04 | -7.60 | 3.66 | -2.37 | 69.55 | -1,287.13 | 28.61 | 0.0377 | -- | 1.68 | -- | 41,225.93 | -55.72 | -15.49 | -- | -- | -- |
| Allakos Inc | 0.00 | -214.44m | 126.62m | 131.00 | -- | 1.21 | -- | -- | -2.45 | -2.45 | 0.00 | 1.18 | 0.00 | -- | -- | 0.00 | -81.27 | -42.71 | -92.78 | -45.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 41.96 | -- | -38.89 | -- |
| FitLife Brands Inc | 58.51m | 7.30m | 127.83m | 37.00 | 18.80 | 4.35 | 17.25 | 2.18 | 1.48 | 1.48 | 11.87 | 6.39 | 1.20 | 3.87 | 27.13 | 1,581,351.00 | 15.03 | 26.40 | 19.37 | 33.92 | 41.55 | 42.09 | 12.48 | 17.65 | 0.5177 | 12.32 | 0.3582 | -- | 82.97 | 25.28 | 19.58 | 67.31 | -- | -- |
| PDS Biotechnology Corp | 0.00 | -43.89m | 130.58m | 25.00 | -- | 3.51 | -- | -- | -1.37 | -1.37 | 0.00 | 1.01 | 0.00 | -- | -- | 0.00 | -63.85 | -51.63 | -74.22 | -59.00 | -- | -- | -- | -- | -- | -27.82 | 0.3933 | -- | -- | -- | -5.11 | -- | -- | -- |
| Vigil Neuroscience Inc | 0.00 | -82.78m | 131.55m | 65.00 | -- | 1.27 | -- | -- | -2.12 | -2.12 | 0.00 | 2.76 | 0.00 | -- | -- | 0.00 | -52.16 | -- | -54.92 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.98 | -- | -- | -- |
| Karyopharm Therapeutics Inc | 140.46m | -146.34m | 131.84m | 325.00 | -- | -- | -- | 0.9386 | -1.28 | -1.28 | 1.22 | -1.45 | 0.5298 | 1.67 | 4.24 | 432,187.70 | -55.19 | -53.02 | -72.56 | -65.85 | 96.08 | 97.18 | -104.18 | -125.15 | 2.99 | -9.66 | 2.25 | -- | -7.03 | 36.93 | 13.43 | -- | -- | -- |
| Citius Pharmaceuticals Inc | 0.00 | -37.35m | 131.89m | 22.00 | -- | 1.46 | -- | -- | -0.2367 | -0.2367 | 0.00 | 0.4989 | 0.00 | -- | -- | 0.00 | -37.14 | -30.26 | -39.48 | -32.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -0.1589 | -- | -- | -- |
| Adicet Bio Inc | 0.00 | -139.79m | 132.30m | 143.00 | -- | 0.5112 | -- | -- | -2.95 | -2.95 | 0.00 | 3.15 | 0.00 | -- | -- | 0.00 | -46.75 | -37.03 | -49.70 | -40.28 | -- | -- | -- | -748.46 | -- | -- | 0.00 | -- | -100.00 | -- | -104.41 | -- | 65.27 | -- |
Data as of May 22 2024. Currency figures normalised to Allakos Inc's reporting currency: US Dollar USD
53.15%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BVF Partners LPas of 31 Mar 2024 | 16.55m | 18.69% |
| Deep Track Capital LPas of 31 Mar 2024 | 5.00m | 5.65% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 4.34m | 4.90% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 3.74m | 4.22% |
| Redmile Group LLCas of 31 Mar 2024 | 3.45m | 3.90% |
| Millennium Management LLCas of 31 Mar 2024 | 3.25m | 3.67% |
| Citadel Advisors LLCas of 31 Mar 2024 | 2.93m | 3.31% |
| Logos Global Management LPas of 31 Mar 2024 | 2.90m | 3.28% |
| Morgan Stanley & Co. LLCas of 31 Mar 2024 | 2.46m | 2.78% |
| Opaleye Management, Inc.as of 31 Mar 2024 | 2.44m | 2.75% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
